CKPT Logo

Checkpoint Therapeutics, Inc. (CKPT) 

NASDAQ
Market Cap
$175.2M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
602 of 958
Rank in Industry
330 of 549

Largest Insider Buys in Sector

CKPT Stock Price History Chart

CKPT Stock Performance

About Checkpoint Therapeutics, Inc.

Checkpoint Therapeutics, Inc., clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. The company's lead antibody product candidate is Cosibelimab, a fully-human monoclonal antibody of IgG1 subtype that directly binds to programmed death ligand-1 (PD-L1) and blocks the PD-L1 interaction with the programmed death receptor-1 and B7.1 receptors; and CK-302, a human agonistic antibody that is designed to bind to and trigger …

Insider Activity of Checkpoint Therapeutics, Inc.

Over the last 12 months, insiders at Checkpoint Therapeutics, Inc. have bought $0 and sold $4.28M worth of Checkpoint Therapeutics, Inc. stock.

On average, over the past 5 years, insiders at Checkpoint Therapeutics, Inc. have bought $0 and sold $1.08M worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 100,000 shares for transaction amount of $127,000 was made by ROSENWALD LINDSAY A MD (director) on 2019‑11‑20.

List of Insider Buy and Sell Transactions, Checkpoint Therapeutics, Inc.

2024-12-19SaleCEO, President and Director
220,230
0.4555%
$3.38$744,3770.00%
2024-12-18SaleCEO, President and Director
602,167
1.3953%
$3.87$2.33M0.00%
2024-12-18SaleChief Financial Officer
268,432
0.6445%
$4.01$1.08M0.00%
2024-06-26SaleCEO, President and Director
24,610
0.0674%
$2.05$50,451+22.22%
2024-06-26SaleChief Financial Officer
13,038
0.0359%
$2.06$26,858+22.22%
2024-02-28SaleCEO, President and Director
5,894
0.0247%
$2.06$12,142+7.07%
2024-02-28SaleChief Financial Officer
2,035
0.0086%
$2.07$4,212+7.07%
2024-02-01SaleCEO, President and Director
11,900
0.0552%
$2.01$23,919+8.67%
2024-02-01SaleChief Financial Officer
4,115
0.0185%
$1.95$8,024+8.67%
2023-03-02SaleCEO, President and Director
5,483
<0.0001%
$5.00$27,415-55.93%
2023-03-02SaleChief Financial Officer
3,591
<0.0001%
$5.00$17,955-55.93%
2023-02-27SaleCEO, President and Director
5,548
<0.0001%
$4.65$25,798-51.41%
2023-02-27SaleChief Financial Officer
1,914
<0.0001%
$4.66$8,919-51.41%
2023-02-01SaleCEO, President and Director
10,261
<0.0001%
$4.77$48,945-50.47%
2023-02-01SaleChief Financial Officer
3,154
<0.0001%
$4.79$15,108-50.47%
2023-01-10SaleCEO, President and Director
3,817
<0.0001%
$6.75$25,761-62.55%
2023-01-10SaleChief Financial Officer
1,858
<0.0001%
$6.75$12,540-62.55%
2022-06-17SaleCEO, President and Director
15,000
0.0183%
$1.11$16,650-44.09%
2022-04-13SaleCEO, President and Director
21,258
0.024%
$1.51$32,100-35.33%
2022-04-05SaleCEO, President and Director
14,030
0.0164%
$1.77$24,833-42.20%

Insider Historical Profitability

32.45%
ROSENWALD LINDSAY A MDdirector
237890
0.4942%
$3.6440+32.45%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Armistice Capital Llc$5.57M7.362.72M+11.95%+$594,500.000.02
The Vanguard Group$1.88M2.49917,894+67.41%+$757,651.42<0.0001
Renaissance Technologies$556,000.000.74271,217+63.65%+$216,248.30<0.01
Geode Capital Management$407,028.000.54198,501+14.18%+$50,559.39<0.0001
BlackRock$339,160.000.45165,444-0.64%-$2,197.60<0.0001
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.